Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Greenwich LifeSciences Q3 2026 Results: Net Loss of $5.81M, Loss Widens

Greenwich LifeSciences reported a net loss of $15.4 million for the nine months ended September 30, 2026, driven primarily by $14.2 million in research and development expenses for its breast cancer immunotherapy. The company raised $9.3 million through an ATM program during the period but issued a going concern warning due to its accumulated deficit of $102.6 million and limited cash reserves of $5.9 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-5.8-3.7
EPS (diluted, $ a share)$-0.40$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GLSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Greenwich LifeSciences, Inc.: key numbers

Share price
$18.70Close, Nov 17
Market cap
$274M
Shares outstanding
14.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.